Tübingen, Germany, Would possibly 11, 2022 Acousia Therapeutics GmbH will likely be presenting knowledge at the corporate’s scientific level, first-in-class lead candidate ACOU085 on the Hanson Wade second Internal Ear Therapeutics Summit to be held in individual in Boston (MA) from June 20–23, 2022.
ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is these days being examined in a Segment 1b scientific trial involving age-related listening to loss (ARHL) sufferers. Designed to modulate a biologically validated goal – the KCNQ4-encoded Kv7.4 potassium channel, which is very important for keeping up auditory serve as – ACOU085 is being advanced for the remedy and prevention of listening to loss for a variety of got and inherited kinds of sensorineural listening to loss.
ACOU085 is characterised through a singular twin mode of motion, which supplies acute purposeful enhancement and long-term coverage for the terminally differentiated sensorineural outer hair cells. “Being invited to proportion the translational background and growth of our ACOU085 lead program with the listening to loss drug construction neighborhood on the Internal Ear Therapeutics Summit is a thrilling alternative for us,” says Dr. Jonas Dyhrfjeld-Johnsen, Leader Construction Officer at Acousia Therapeutics. “I sit up for stimulating discussions with our friends in Boston.”
Along with receiving a call for participation to offer “Small Molecule, KCNQ4 Agonist ACOU085 for the Remedy and Prevention of Listening to Loss”, Dr. Dyhrfjeld-Johnsen may also take part as a panelist at the panel dialogue “De-risking the Early Construction Procedure: A Powerful and Complete Early Construction Procedure Is Very important to Reduce Setbacks Confronted within the Health facility” and within the workshop “Thoughts The Hole: Calling Out the Shortfalls within the Present Internal Ear Healing Construction Pathway and Illuminating Answers”.
About Acousia Therapeutics
Acousia Therapeutics GmbH is a privately-held, scientific level biotech corporate based totally in Tübingen, Germany. The corporate is devoted to the identity and construction of small molecules for efficient prevention and remedy of various etiologies of listening to loss. Acousia Therapeutics develops medicine for native and systemic management.
Touch
Tim Boelke, M.D.
boelke@acousia.com
+49 70712988186
www.acousia.com
